{"id":384593,"date":"2020-11-18T19:04:53","date_gmt":"2020-11-19T00:04:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384593"},"modified":"2020-11-18T19:04:53","modified_gmt":"2020-11-19T00:04:53","slug":"prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/","title":{"rendered":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001"},"content":{"rendered":"
\n

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc.<\/a> (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on\u00a0November 17, 2020\u00a0issued a composition of matter patent, U.S. Patent No. 10,837,028,\u00a0with claims directed to the AAV vector used in PR001, Prevail\u2019s experimental gene therapy program for the treatment of Parkinson\u2019s disease with GBA1<\/em> mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings.<\/p>\n

\u201cWe are excited to make important progress this year with PR001, which is being evaluated in the Phase 1\/2 PROPEL trial for patients with Parkinson\u2019s disease with GBA1<\/em> mutations and in the Phase 1\/2 PROVIDE trial for patients with Type 2 Gaucher disease,\u201d said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. \u201cWe are advancing clinical development of PR001 to make a potentially transformative difference for these patients who currently have no approved treatment options.\u201d<\/p>\n

The Company recently announced that patient dosing has continued in the Phase 1\/2 PROPEL clinical trial of PR001 for PD-GBA patients, and it expects to provide the next biomarker and safety analysis on a subset of patients in the PROPEL trial by mid-2021. The Company expects to initiate enrollment of the Phase 1\/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for nGD in 2021.<\/p>\n

The U.S. Food and Drug Administration has granted Fast Track designations for PR001 for the treatment of PD-GBA and nGD. In addition, the FDA granted PR001 Rare Pediatric Disease\u00a0designation for the treatment of nGD, and Orphan Drug\u00a0designation for the treatment of patients with Gaucher disease.<\/p>\n

\n About Prevail Therapeutics<\/strong>
\n
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinson\u2019s disease with GBA1\u00a0<\/em>mutations (PD-GBA) and neuronopathic Gaucher disease (nGD); PR006 for patients with frontotemporal dementia with\u00a0GRN\u00a0<\/em>mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.<\/p>\n

Prevail was founded by Dr.\u00a0Asa Abeliovich\u00a0in 2017, through a collaborative effort with\u00a0The Silverstein Foundation\u00a0for Parkinson\u2019s with GBA and OrbiMed, and is headquartered in\u00a0New\u00a0York, NY.<\/p>\n

\n Forward-Looking Statements Related to Prevail<\/strong>
\n
Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning the potential for Prevail\u2019s gene therapy candidates to make a transformative difference for patients with neurodegenerative diseases; the expected timing of reporting additional interim data on a subset of patients from the PROPEL trial; and the anticipated timing of enrollment of and the next update on data from the PROVIDE trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevail\u2019s novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevail\u2019s gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevail\u2019s filings with the Securities and Exchange Commission (SEC), including the \u201cRisk Factors\u201d sections of the Company\u2019s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n

\n Media Contact:<\/strong>
\n
Lisa Qu
Ten Bridge Communications
LQu@tenbridgecommunications.com<\/a>
678-662-9166<\/p>\n

\n Investor Contact:<\/strong>
\n
\n investors@prevailtherapeutics.com<\/a>\n <\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on\u00a0November 17, 2020\u00a0issued a composition of matter patent, U.S. Patent No. 10,837,028,\u00a0with claims directed to the AAV vector used in PR001, Prevail\u2019s experimental gene therapy program for the treatment of Parkinson\u2019s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings. \u201cWe are excited to make important progress this year with PR001, which is being evaluated in the Phase 1\/2 PROPEL trial … <\/p>\n

Continue reading “Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384593","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPrevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on\u00a0November 17, 2020\u00a0issued a composition of matter patent, U.S. Patent No. 10,837,028,\u00a0with claims directed to the AAV vector used in PR001, Prevail\u2019s experimental gene therapy program for the treatment of Parkinson\u2019s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings. \u201cWe are excited to make important progress this year with PR001, which is being evaluated in the Phase 1\/2 PROPEL trial … Continue reading "Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T00:04:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001\",\"datePublished\":\"2020-11-19T00:04:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/\"},\"wordCount\":756,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/\",\"name\":\"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=\",\"datePublished\":\"2020-11-19T00:04:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/","og_locale":"en_US","og_type":"article","og_title":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - Market Newsdesk","og_description":"NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on\u00a0November 17, 2020\u00a0issued a composition of matter patent, U.S. Patent No. 10,837,028,\u00a0with claims directed to the AAV vector used in PR001, Prevail\u2019s experimental gene therapy program for the treatment of Parkinson\u2019s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings. \u201cWe are excited to make important progress this year with PR001, which is being evaluated in the Phase 1\/2 PROPEL trial … Continue reading \"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T00:04:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001","datePublished":"2020-11-19T00:04:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/"},"wordCount":756,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/","name":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=","datePublished":"2020-11-19T00:04:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NiMzODMzOTM0IzIxODM1OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prevail-therapeutics-granted-composition-of-matter-patent-for-experimental-gene-therapy-program-pr001\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384593"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384593\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}